Skip to main content
BIOME AUSTRALIA LIMITED logo

BIOME AUSTRALIA LIMITED — Investor Relations & Filings

Ticker · BIO ISIN · AU0000184137 ASX Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country AU Australia
Listing ASX BIO

About BIOME AUSTRALIA LIMITED

https://www.biomeaustralia.com

Biome Australia Limited is a microbiome health company specializing in the development and distribution of evidence-based probiotics and complementary medicines. The company focuses on translating microbiome science into accessible healthcare solutions through its flagship brand, Activated Probiotics. Its product portfolio consists of condition-specific formulations designed to address various health areas, including digestive health, immune system support, bone density, and mental wellbeing via psychobiotics. Biome Australia prioritizes clinical research and collaborates with global experts to ensure the efficacy of its formulations. The company’s distribution strategy centers on a network of community pharmacies and independent health practitioners, providing professional-grade supplements to the retail and clinical markets.

Recent filings

Filing Released Lang Actions
Investor Webinar 3 pages 222.1KB
Regulatory Filings Classification · 12% confidence The document is a short ASX announcement inviting investors to a webinar on the BMB18 clinical program and IP strategy. It contains no financial data or detailed report content, nor is it a meeting materials or earnings release. It is neither the presentation itself nor a regulatory certification. It is a general corporate announcement, fitting the fallback category for miscellaneous regulatory notices. Therefore, it is classified as Regulatory Filings (RNS).
2026-05-26 English
BMB18 clinical trial expands to dual site 4 pages 170.9KB
Regulatory Filings Classification · 92% confidence The document is a corporate ASX announcement providing a material update on the commencement of a clinical trial. It does not present financial results, call transcripts, board changes, M&A activity, dividends, or filings of detailed financial statements. It is a general disclosure to the market under continuous disclosure obligations, fitting the catch-all category of a regulatory announcement. Therefore, the correct classification is Regulatory Filings (RNS).
2026-05-26 English
Probiotical Exclusive Supply Agreement Extended 3 pages 208.7KB
Regulatory Filings Classification · 91% confidence The document is an ASX announcement regarding the extension of an exclusive supply agreement with Probiotical SpA. It is not a financial report (annual, interim, earnings), nor does it cover dividends, share transactions, M&A, board changes, or fundraising. It is a general corporate announcement published via a regulatory exchange, fitting the fallback category for miscellaneous filings. Therefore, it is classified as a Regulatory Filing (RNS).
2026-05-11 English
Change of Director's Interest Notice 2 pages 335.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, the nature of the interest, and transaction details such as on-market purchase. This type of document is a report of personal share transactions by company directors and executives, commonly known as a Director's Dealing report. The document length is 3459 characters, which is consistent with a detailed notice of director's interest changes rather than a full financial report or other filing types. Therefore, the correct classification is Director's Dealing (DIRS).
2026-04-29 English
Change of Director's Interest Notice 2 pages 335.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market purchase), and other related information. There is no financial performance data, earnings information, or report publication details. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing' filings. The document length is 3461 characters, which is consistent with a notice rather than a full report. Therefore, the correct classification is DIRS (Director's Dealing).
2026-04-28 English
Quarterly Activities & Cashflow Report 15 pages 1.6MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 28 April 2026 titled 'Quarterly Activities & Appendix 4C March 2026'. It provides a detailed quarterly update on company activities, operational metrics, market position, clinical trials, international markets, and financial updates including cash position and director payments. The document references the quarter ended 31 March 2026 and discusses quarterly performance indicators and outlook. It includes substantive financial and operational data for the quarter, not just a brief announcement or link to a report. The presence of Appendix 4C (a quarterly cash flow report required by ASX) and detailed quarterly operational and financial commentary indicates this is a comprehensive quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.